Arcutis scores FDA approval for new foam treatment for common skin condition

Zachary Brennan

Senior Editor

California-based Arcutis Biotherapeutics on Friday won FDA approval for a new foam-based skin treatment for seborrheic dermatitis in individuals 9 years of age and older …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Arcutis scores FDA approval for new foam treatment for common skin condition

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Ar­cutis scores FDA ap­proval for new foam treat­ment for com­mon skin con­di­tion

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Arcutis scores FDA approval for new foam treatment for common skin condition